Sensitive

Response to Pazopanib in cancer (hepatotoxicity)

AGER · rs1800625

What each result means

A/A Published research associates this genotype with typical/baseline likelihood of Response to Pazopanib in cancer (hepatotoxicity) — no copies of the reported risk allele. (GWAS Catalog, Clin Cancer Res 2015, PMID:26546620)
A/G Published research associates this genotype (one copy of the reported risk allele) with an intermediate association with Response to Pazopanib in cancer (hepatotoxicity). (GWAS Catalog, Clin Cancer Res 2015, PMID:26546620)
G/G Published research associates this genotype (two copies of the reported risk allele) with a higher likelihood of Response to Pazopanib in cancer (hepatotoxicity) compared to the general population. (GWAS Catalog, Clin Cancer Res 2015, PMID:26546620)

Source: GWAS Catalog, Clin Cancer Res 2015, PMID:26546620

Questions about rs1800625

What is rs1800625?

rs1800625 is a single position in the genome, in or near the AGER gene. Published research associates it with response to pazopanib in cancer (hepatotoxicity). A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.

Does having rs1800625 mean I will get this?

No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.

Where does the information about rs1800625 come from?

GWAS Catalog, Clin Cancer Res 2015, PMID:26546620. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.

← See all variants